公开(公告)号：US10179172B2

公开(公告)日：2019-01-15

申请号：US14483880

申请日：2014-09-11

Applicant: EAGLE BIOLOGICS, INC.

Inventor： Alyssa M. Larson ,  Kevin Love ,  Alisha K. Weight ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K39/395 ,  A61K47/06 ,  A61K47/24 ,  A61K9/00 ,  A61K47/20 ,  A61K47/22 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  A61K47/18 ,  A61K9/19 ,  C07K16/32 ,  A61K38/00

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes.

公开(公告)号：US20180085463A1

公开(公告)日：2018-03-29

申请号：US15809602

申请日：2017-11-10

Applicant: Eagle Biologics, Inc.

Inventor： Alyssa M. Larson ,  Kevin Love ,  Alisha K. Weight ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K47/06 ,  C07K16/32 ,  C07K16/28 ,  C07K16/24 ,  C07K16/22 ,  A61K9/00 ,  A61K47/22 ,  A61K47/20 ,  A61K47/18 ,  A61K39/395 ,  A61K47/24 ,  A61K9/19 ,  A61K38/00

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.

公开(公告)号：US20240285766A1

公开(公告)日：2024-08-29

申请号：US18635538

申请日：2024-04-15

Applicant: Eagle Biologics, Inc.

Inventor： Alyssa M. Larson ,  Kevin Love ,  Alisha K. Weight ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K47/06 ,  A61K9/00 ,  A61K9/19 ,  A61K38/00 ,  A61K39/395 ,  A61K47/20 ,  A61K47/22 ,  A61K47/24 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K47/06 ,  A61K9/0019 ,  A61K9/19 ,  A61K39/3955 ,  A61K47/20 ,  A61K47/22 ,  A61K47/24 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2839 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  A61K38/00

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.

公开(公告)号：US11986526B2

公开(公告)日：2024-05-21

申请号：US17073618

申请日：2020-10-19

Applicant: Eagle Biologics, Inc.

Inventor： Alyssa M. Larson ,  Kevin Love ,  Alisha K. Weight ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K39/395 ,  A61K9/00 ,  A61K9/19 ,  A61K47/06 ,  A61K47/20 ,  A61K47/22 ,  A61K47/24 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  A61K38/00

CPC classification number: A61K47/06 ,  A61K9/0019 ,  A61K9/19 ,  A61K39/3955 ,  A61K47/20 ,  A61K47/22 ,  A61K47/24 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2839 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  A61K38/00

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.

公开(公告)号：US20210038718A1

公开(公告)日：2021-02-11

申请号：US17067058

申请日：2020-10-09

Applicant: EAGLE BIOLOGICS, INC.

Inventor： Alyssa M. Larson ,  Alisha K. Weight ,  Kevin Love ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K47/06 ,  A61K9/00 ,  A61K9/19 ,  A61K39/395 ,  A61K47/20 ,  A61K47/22 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  A61K47/24

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.

公开(公告)号：US20210030877A1

公开(公告)日：2021-02-04

申请号：US17073618

申请日：2020-10-19

Applicant: Eagle Biologics, Inc.

Inventor： Alyssa M. Larson ,  Kevin Love ,  Alisha K. Weight ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K47/06 ,  A61K9/19 ,  C07K16/32 ,  A61K47/24 ,  A61K9/00 ,  A61K39/395 ,  A61K47/20 ,  A61K47/22 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.

公开(公告)号：US20180177876A1

公开(公告)日：2018-06-28

申请号：US15903635

申请日：2018-02-23

Applicant: Eagle Biologics, Inc.

Inventor： Alyssa M. Larson ,  Kevin Love ,  Alisha K. Weight ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K47/06 ,  C07K16/28 ,  A61K9/19 ,  A61K47/18

CPC classification number: A61K47/06 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K39/3955 ,  A61K47/186 ,  A61K47/20 ,  A61K47/22 ,  A61K47/24 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2839 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

公开(公告)号：US10849977B2

公开(公告)日：2020-12-01

申请号：US15903635

申请日：2018-02-23

Applicant: Eagle Biologics, Inc.

Inventor： Alyssa M. Larson ,  Kevin Love ,  Alisha K. Weight ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K39/395 ,  A61K47/06 ,  A61K9/19 ,  C07K16/32 ,  A61K47/24 ,  A61K9/00 ,  A61K47/20 ,  A61K47/22 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  A61K38/00

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

公开(公告)号：US10646571B2

公开(公告)日：2020-05-12

申请号：US15903523

申请日：2018-02-23

Applicant: Eagle Biologics, Inc.

Inventor： Alyssa M. Larson ,  Kevin Love ,  Alisha K. Weight ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K39/395 ,  A61K47/06 ,  A61K9/19 ,  C07K16/32 ,  A61K47/24 ,  A61K9/00 ,  A61K47/20 ,  A61K47/22 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  A61K47/18 ,  A61K38/00

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

公开(公告)号：US20180153997A1

公开(公告)日：2018-06-07

申请号：US15890044

申请日：2018-02-06

Applicant: EAGLE BIOLOGICS, INC.

Inventor： Alyssa M. Larson ,  Alisha K. Weight ,  Kevin Love ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K47/06 ,  C07K16/32 ,  C07K16/28 ,  C07K16/24 ,  C07K16/22 ,  A61K9/00 ,  A61K47/22 ,  A61K47/20 ,  A61K47/18 ,  A61K39/395 ,  A61K47/24 ,  A61K9/19 ,  A61K38/00

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.